Artikel ; Online: Patient‐level indirect treatment comparison of lanadelumab versus pdC1‐INH i.v. in hereditary angioedema patients: PATCH study
Allergy. 2024 Jan., v. 79, no. 1, p. 215-224
2024 , Seite(n) 215–224
Abstract: BACKGROUND: Hereditary angioedema (HAE) is an autosomal dominant inherited disease in which patients suffer from local attacks primarily affecting skin and gastrointestinal tract, and sometimes even the upper respiratory tract leading to asphyxiation. ... ...
| Abstract | BACKGROUND: Hereditary angioedema (HAE) is an autosomal dominant inherited disease in which patients suffer from local attacks primarily affecting skin and gastrointestinal tract, and sometimes even the upper respiratory tract leading to asphyxiation. Since head‐to‐head trials between authorized treatments are lacking, this study compares efficacy and safety of lanadelumab and intravenous plasma‐derived C1‐esterase inhibitor (pdC1‐INH i.v.) in HAE patients on long‐term prophylaxis by means of an indirect treatment comparison. METHODS: Efficacy and safety of lanadelumab against pdC1‐INH i.v. were analyzed in a fully prespecified indirect comparison based on individual patient data (n = 231) from the HELP and CHANGE clinical trials. Primary and secondary efficacy endpoints were compared using a generalized linear model for count data. Confounding variables were identified a priori via systematic literature research and validated by clinical experts. Adjustment of confounders was implemented using a conditional regression model. RESULTS: Lanadelumab showed a statistically significant improvement in reduction of HAE attack rates compared to pdC1‐INH i.v. across multiple endpoints: Monthly attack rate of patients treated with lanadelumab was less than half compared to pdC1‐INH i.v. (Rate ratio: 0.486; 95% CI: 0.253, 0.932). Monthly rate of laryngeal attacks was found to be five times lower for lanadelumab (Rate ratio: 0.2; 95% CI: 0.044, 0.915) and monthly rate of acute treated HAE attacks among lanadelumab patients was about one third of the attack rate of pdC1‐INH i.v. patients (Rate ratio: 0.366; 95% CI: 0.185, 0.727). CONCLUSION: This study contributes to current knowledge in the treatment of HAE by indicating a statistically significant reduction of HAE attacks under lanadelumab compared to pdC1‐INH i.v. |
|---|---|
| Schlagwörter | asphyxia ; digestive tract ; disease prevention ; genetic disorders ; hypersensitivity ; intravenous injection ; larynx ; linear models ; patients ; regression analysis |
| Sprache | Englisch |
| Erscheinungsverlauf | 2024-01 |
| Umfang | p. 215-224 |
| Erscheinungsort | John Wiley & Sons, Ltd |
| Dokumenttyp | Artikel ; Online |
| Anmerkung | JOURNAL ARTICLE |
| ZDB-ID | 391933-x |
| ISSN | 1398-9995 ; 0105-4538 |
| ISSN (online) | 1398-9995 |
| ISSN | 0105-4538 |
| DOI | 10.1111/all.15861 |
| Datenquelle | NAL Katalog (AGRICOLA) |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Uh III Zs.150: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 125: Hefte anzeigen |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.